Document:

Exhibit 4.4

    

    

    

    COMMON STOCK PURCHASE WARRANT

    

    

     CHEMBIO DIAGNOSTICS, INC.

     

    

    
      	
              Warrant Shares: _______

            	
              Issue Date: _______, 2022

            

      

    

    

    THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____ or its assigns (the “Holder”) is entitled, upon
      the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Common Warrants Initial Exercise Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on
      the five (5) year anniversary of the Common Warrants Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Chembio Diagnostics, Inc., a Nevada corporation (the “Company”), up to ______
      shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).  This Warrant shall
      initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s right to elect to
      receive a Warrant in certificated form pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.

     

        

    Section 1.          Definitions.  In addition to the terms
        defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:

     

    

    “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is
      under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

     

    

    “Authorization Increase” means, subject to Stockholder Approval, an increase in the number of authorized shares of Common Stock of
      the Company by the Company’s filing of the Certificate of Amendment with the Secretary of State of the State of Nevada and the acceptance thereof, provided that the amount of such increase shall be determined by the Board of Directors and shall be
      sufficient for the issuance of all of the Common Warrant Shares (as defined in the Underwriting Agreement) upon exercise in full of the Common Warrants (as defined in the Underwriting Agreement).

     

    

    “Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
      is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on
      a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or
      OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of
      reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a
      majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

    
      1

      
        

    

    “Board of Directors” means the board of directors of the Company.

     

    

    “Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are
      authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential
      employee”  or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks
      in The City of New York generally are open for use by customers on such day.

     

    

    “Certificate of Amendment” means the amendment to the Company’s Articles of Incorporation that effects the Reverse Stock Split
      and/or the Authorization Increase.

     

    

    “Commission” means the United States Securities and Exchange Commission.

     

    

    “Common Stock” means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
      securities may hereafter be reclassified or changed.

     

    

    “Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
      acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof
      to receive, Common Stock.

     

    

    “Common Warrants Initial Exercise Date” means the first date on which both Stockholder Approval and Nasdaq Stockholder Approval
      have been obtained and Authorization Increase and/or Reverse Stock Split are deemed effective in accordance with the laws of the State of Nevada.

     

    

    “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

    

    

    “Exempt Issuance” means the issuance of (a) shares of Common Stock or options or other equity awards to employees, officers,
      consultants or directors of the Company (i) pursuant to any stock or option plan or other equity incentive plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors or a majority of the members of a
      committee of non-employee directors established for such purpose for services rendered to the Company or (ii) made as a material inducement to a grantee’s entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) (or
      any successor to such rule), (b) securities upon the exercise or exchange of or conversion of any securities issued pursuant to the Underwriting Agreement and/or other securities exercisable or exchangeable for or convertible into shares of Common
      Stock issued and outstanding on the issuance date of this Warrant, provided that such securities have not been amended since the issuance date of this Warrant to increase the number of such securities or to decrease the exercise price, exchange price
      or conversion price of such securities or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such
      securities are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith until the earlier of (a) the date that is the six (6)
      month anniversary of the issuance date of this Warrant and (b) the Common Warrants Initial Exercise Date, and provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its
      subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in
      which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.

     

    

    “Nasdaq Stockholder Approval” means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock
      Market (or any successor entity) from the stockholders of the Company with respect to the issuance of the Common Warrants (as defined in the Underwriting Agreement) and the Common Warrant Shares (as defined in the Underwriting Agreement) upon
      exercise thereof.

    

    
      2

      
        

    

    “Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited
      liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

     

    

    “Registration Statement” means the Company’s registration statement on Form S-1 (File No. 333-267320).

     

    

    “Reverse Stock Split Date” means the first date on which a Reverse Stock Split is deemed effective in accordance with the laws of
      the State of Nevada (it being understood that, if the Company effects a second reverse stock split of the Common Stock subsequent to the Reverse Stock Split Date, such second reverse stock split would not be a Reverse Stock Split Date for purposes of
      this Warrant).

    

     

    

    “Reverse Stock Split” means, subject to Stockholder Approval, a reverse stock split of the outstanding shares of Common Stock that
      is effected by the Company’s filing of the Certificate of Amendment with the Secretary of State of the State of Nevada and the acceptance thereof, which reverse stock split shall have a ratio as determined by the Board of Directors and shall be
      sufficient for the issuance in full of the Common Warrant Shares (as defined in the Underwriting Agreement) upon exercise in full of the Common Warrants (as defined in the Underwriting Agreement).

     

    

    “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

     

    

    “Stockholder Approval” means such approval as may be required by the laws of the State of Nevada from the stockholders of the
      Company with respect to the Authorization Increase and/or the Reverse Stock Split, and such approval is deemed effective in accordance with the laws of the State of Nevada.

     

    

    “Subsidiary” means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the
      Company formed or acquired after the date hereof.

     

    

    “Trading Day” means a day on which the Common Stock is traded on a Trading Market.

     

    

    “Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the
      date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).

     

    

    “Transfer Agent” means Action Stock Transfer Corp., the current transfer agent of the Company, with a mailing address of 2469 E.
      Fort Union Blvd., Suite 214, Salt Lake City, UT 84121, and any successor transfer agent of the Company.

     

    

    “Trigger Date” means the sixth (6th) Trading Day immediately following the Reverse Stock Split Date. 

    

     

    

    “Underwriting Agreement” means the underwriting agreement, dated as of _________, 2022, among the Company and Craig-Hallum Capital
      Group LLC as representative of the underwriters named therein, as amended, modified or supplemented from time to time in accordance with its terms.

     

    

    “VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is
      then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg
      L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date)
      on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its
      functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the
      holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

    
      3

      
        

    

    “Warrant Agency Agreement” means that certain warrant agency agreement, dated on or about the Initial Exercise Date, between the
      Company and the Warrant Agent.

     

    

    “Warrant Agent” means the Transfer Agent and any successor warrant agent of the Company.

     

    

    “Warrants” means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration
      Statement.

     

    

    Section 2.             Exercise.

     

      

    
      
        a)          Exercise of
              Warrant.  Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of
          a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i)
          two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
          shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No
          ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.  Notwithstanding anything herein to the contrary, the Holder shall not be
          required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the
          Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
          available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.  The Holder and the Company shall maintain records
          showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice.  The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder,
            the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

      

    

     

    

    The Holder and any such assignee, by acceptance of this Warrant, further acknowledge and agree that (i) an
      Authorization Increase or Reverse Stock Split may never occur, (ii) Nasdaq Stockholder Approval may never occur, (iii) as a result, the Common Warrants Initial Exercise Date may never occur and this Warrant may never become exercisable, and (iii) the
      Company shall have no liability or other obligation to the Holder or such assignee as a result thereof.

     

    

    Notwithstanding the foregoing in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s)
      representing this Warrant held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect exercises made pursuant to this Section 2(a) by delivering to DTC (or such other clearing
      corporation, as applicable) the appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation, as applicable), subject to a Holder’s right to elect to receive
      a Warrant in certificated form pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall not apply.

     

    

    
      
        b)           Exercise
              Price.  The exercise price per share of Common Stock under this Warrant shall be $_____, subject to adjustment hereunder (the “Exercise Price”). In addition,
          on the Trigger Date, the Exercise Price shall be reduced, and only reduced, to the lesser of (i) the then Exercise Price and (ii) the lowest VWAP on any Trading Day during the five (5) Trading Day period immediately prior to the Trigger Date (the
          “Reset Exercise Price”, which shall thereafter be the new Exercise Price, subject to further adjustment hereunder, and such five (5) Trading Day period shall be referred to herein as the “Measurement Period”). The Company shall notify each
          Holder of the applicable adjustment to the Exercise Price as of such date and include the applicable adjusted number of Warrant Shares as of such date (each notice, a “Trigger Date Adjustment Notice”). For purposes of clarification,
          whether or not the Company provides a Trigger Date Adjustment Notice pursuant to this Section 2(b), each Holder shall only be required to pay the Reset Exercise Price with respect to such exercise, regardless of whether a Holder accurately refers
          to such price in any Notice of Exercise. If the aggregate Exercise Price paid by the Holder exceeds the amount that should have been paid based on the Reset Exercise Price, the Company shall promptly return any excess aggregate Exercise Price to
          the Holder. Any adjustment to the Exercise Price pursuant to this Section shall be effective retroactively to the first Trading Day during such Measurement Period.

        

        
          4

          
            

        

      

    

    
      
        c)           Cashless
              Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may
          also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

      

    

     

    

    (A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice
      of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as
      defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution
      of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on
      a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section
      2(a) hereof after the close of “regular trading hours” on such Trading Day;

    

    

    (B) = the Exercise Price of this Warrant, as adjusted hereunder; and

    

    

    (X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this
      Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

    

    

    If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
      Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.  The Company agrees not to take any position contrary to this Section 2(c).

    

    

    Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless
      exercise pursuant to this Section 2(c).

    

    

    
      
        d)        Mechanics of Exercise.

         

        

      

    

    
      
        
          
            i.            Delivery of Warrant Shares Upon Exercise.  The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting
              the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the
              Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via
              cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such
              exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the
              aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”).   Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to
              which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two
              (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.  The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as
              this Warrant remains outstanding and exercisable.  As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading
              Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

          

        

      

    

    
      
        
          5

          
            

        

        
          
            ii.          Delivery of
                  New Warrants Upon Exercise.  If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares,
              deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

          

        

      

    

    
      
         

          

        
          
            iii.         Rescission Rights.  If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
              to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

          

        

      

    

    
      
         

          

        
          
            iv.        Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise.  In addition to any other rights available
              to the Holder, if the Company fails to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the
              Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares
              which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s
              total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder
              in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number
              of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with
              its exercise and delivery obligations hereunder.  For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate
              sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the
              amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.  Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in
              equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms
              hereof.

          

        

      

    

    
      
         

          

        v.            No Fractional Shares or Scrip.  No fractional shares or scrip representing
          fractional shares shall be issued upon the exercise of this Warrant.  As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in
          respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

      

    

    
      
         

          

        vi.          Charges, Taxes and Expenses.  Issuance of Warrant Shares shall be made without
          charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of
          the Holder or in such name or names as may be directed by the Holder; provided, however, that, in
          the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
          require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.  The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to
          the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

      

    

    
      
         

          

        vii.         Closing of Books.  The Company will not close its stockholder books or records in any
          manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

      

    

    
      
        
          6

          
            

        

        e)         Holder’s Exercise Limitations.  The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to
            such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons,
            “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of the foregoing sentence, the number of
            shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made,
            but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)
            exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other  Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the
            limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.  Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
            accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
            13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.   To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant
            is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a
            Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this
            Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.  In addition, a determination as to any group status as
            contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.  For purposes of this Section 2(e), in determining the number of outstanding shares of Common
            Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the
            Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.  Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm
            orally and in writing to the Holder the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
            Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.  The “Beneficial

                Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
            of Common Stock issuable upon exercise of this Warrant.  The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in
            no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e)
            shall continue to apply.  Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the
            Company.  The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or
            inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a
            successor holder of this Warrant.

      

    

     

        

    Section 3.           Certain Adjustments.

    
      
         

          

        a)         Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent
            securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger
            number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the
            Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the
            denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
            Warrant shall remain unchanged.  Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become
            effective immediately after the effective date in the case of a subdivision, combination or re‐classification.

      

    

    
      
        
          7

          
            

        

        b)        Adjustment Upon Issuance of Shares of Common Stock. If and whenever on or after the issue date of this Warrant (the “Issuance Date”), the Company issues or sells (or enters into any agreement to
            grant, issue or sell), or in accordance with this Section 3(b) is deemed to have issued or sold, any shares of Common Stock and/or Common Stock Equivalents (including the issuance or sale of shares of Common Stock owned or held by or for the
            account of the Company, but excluding any Exempt Issuance issued or sold or deemed to have been issued or sold) for a consideration per share (the “New Issuance Price”)
            less than a price equal to the Exercise Price in effect immediately prior to such issuance or sale or deemed issuance or sale (such Exercise Price then in effect is referred to herein as the “Applicable Price”) (the foregoing a “Dilutive Issuance”), then simultaneously with the consummation (or, if earlier, the announcement)
            of each such Dilutive Issuance, the Exercise Price then in effect shall be reduced to an amount equal to the New Issuance Price. For all purposes of the foregoing (including, without limitation, determining the adjusted Exercise Price and the
            New Issuance Price under this Section 3(b)), the following shall be applicable:

      

    

    
      
         

          

        (i)        Issuance of Options. If the Company in any manner grants or sells any rights, warrants or options to subscribe for or purchase shares of preferred stock and/or Common Stock or Common Stock Equivalents (“Options”) and the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Common Stock
            Equivalents issuable upon exercise of any such Option or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the
            Company at the time of the granting or sale of such Option for such price per share. For purposes of this Section 3(b)(i), the “lowest price per share for which one share of Common Stock is issuable upon the exercise of any such Options or upon
            conversion, exercise or exchange of any Common Stock Equivalents issuable upon exercise of any such Option or otherwise pursuant to the terms thereof” shall be equal to the lower of (x) the sum of the lowest amounts of consideration (if any)
            received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Common Stock Equivalents issuable upon
            exercise of such Option or otherwise pursuant to the terms thereof and (y) the lowest exercise price set forth in such Option for which one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or
            exchange of any Common Stock Equivalents issuable upon exercise of any such Option or otherwise pursuant to the terms thereof. Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of
            such shares of Common Stock or of such Common Stock Equivalents upon the exercise of such Options or otherwise pursuant to the terms of or upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such
            Common Stock Equivalents. This Section 3(b)(i) shall not apply to any Exempt Issuance.

      

    

    
      
         

          

        (ii)       Issuance of Common Stock Equivalents. If the Company in any manner issues or sells any Common Stock Equivalents and the lowest price per share for which one share of Common Stock is at any time issuable upon the conversion, exercise or exchange thereof or
            otherwise pursuant to the terms thereof is less than the Exercise Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the issuance or sale of such Common Stock
            Equivalents for such price per share. For the purposes of this Section 3(b)(ii), the “lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms
            thereof” shall be equal to (1) the lower of (x) the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to one share of Common Stock upon the issuance or sale of the Common Stock Equivalent and
            upon conversion, exercise or exchange of such Common Stock Equivalent or otherwise pursuant to the terms thereof and (y) the lowest conversion price set forth in such Common Stock Equivalent for which one share of Common Stock is issuable upon
            conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder of such Common Stock Equivalent (or any other Person) upon the issuance or sale of such Common
            Stock Equivalent plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Common Stock Equivalent (or any other Person). Except as contemplated below, no further adjustment of the Exercise
            Price shall be made upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Common Stock Equivalents or otherwise pursuant to the terms thereof, and if any such issuance or sale of such Common Stock
            Equivalents is made upon exercise of any Options for which adjustment of the Warrant has been or is to be made pursuant to other provisions of this Section 3(b), except as contemplated below, no further adjustment of the Exercise Price shall be
            made by reason of such issuance or sale.

      

    

    
      
         

          

        (iii)      Change in Option Price or Rate of Conversion. If the purchase or exercise price provided for in any Options, the additional consideration, if any, payable upon the issue, conversion, exercise or exchange of any Common Stock Equivalents, or the rate at which any
            Common Stock Equivalents are convertible into or exercisable or exchangeable for shares of Common Stock increases or decreases at any time (other than proportional changes in conversion or exercise prices, as applicable, in connection with an
            event referred to in Section 3(a)), the Exercise Price in effect at the time of such increase or decrease shall be adjusted to the Exercise Price which would have been in effect at such time had such Options or Common Stock Equivalents provided
            for such increased or decreased purchase price, additional consideration or increased or decreased conversion rate, as the case may be, at the time initially granted, issued or sold. For purposes of this Section 3(b)(iii), if the terms of any
            Option or Common Stock Equivalents that was outstanding as of the Issuance Date are increased or decreased in the manner described in the immediately preceding sentence, then such Option or Common Stock Equivalents and the shares of Common
            Stock deemed issuable upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the date of such increase or decrease. No adjustment pursuant to this Section 3(b) shall be made if such adjustment would result in an
            increase of the Exercise Price then in effect

      

    

    
      
        
          8

          
            

        

        (iv)      Calculation of Consideration Received. If any Option and/or Common Stock Equivalents and/or Adjustment Right (as defined below) is issued in connection with the issuance or sale or deemed issuance or sale of any other securities of the Company (as
            determined by the Holder, the “Primary Security”, and such Option and/or Common Stock Equivalents and/or Adjustment Right, the “Secondary Securities” and together with the Primary Security, each a “Unit”), together comprising one integrated transaction, the
            aggregate consideration per share of Common Stock with respect to such Primary Security shall be deemed to be the lowest of (x) the purchase price of such Unit, (y) if such Primary Security is an Option and/or Common Stock Equivalent, the
            lowest price per share for which one share of Common Stock is at any time issuable upon the exercise or conversion of the Primary Security in accordance with Section 3(b)(i) or 3(b)(ii) above and (z) the lowest VWAP on any Trading Day during
            the five (5) Trading Day period (the “Adjustment Period”) immediately following the public announcement of such Dilutive Issuance (for the avoidance of doubt, (i) if such
            public announcement is released prior to the opening of the applicable Trading Market on a Trading Day, such Trading Day shall be the first Trading Day in such five Trading Day period and (ii) if this Warrant is exercised on any given Trading
            Day during any such Adjustment Period, solely with respect to such portion of this Warrant exercised on such applicable Trading Day, such applicable Adjustment Period shall be deemed to have ended on, and included, the Trading Day immediately
            prior to such Trading Day on which such exercise occurred). If any shares of Common Stock, Options or Common Stock Equivalents are issued or sold or deemed to have been issued or sold for cash, the consideration received therefor will be deemed
            to be the net amount of consideration received by the Company therefor. If any shares of Common Stock, Options or Common Stock Equivalents are issued or sold for a consideration other than cash, the amount of such consideration received by the
            Company will be the fair value of such consideration, except where such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company for such securities will be the arithmetic average
            of the VWAPs of such security for each of the five (5) Trading Days immediately preceding the date of receipt. If any shares of Common Stock, Options or Common Stock Equivalents are issued to the owners of the non-surviving entity in connection
            with any merger in which the Company is the surviving entity, the amount of consideration therefor will be deemed to be the fair value of such portion of the net assets and business of the non-surviving entity as is attributable to such shares
            of Common Stock, Options or Common Stock Equivalents (as the case may be). The fair value of any consideration other than cash or publicly traded securities will be determined jointly by the Company and the Holder.  If such parties are unable
            to reach agreement within ten (10) days after the occurrence of an event requiring valuation (the “Valuation Event”), the fair value of such consideration will be
            determined within five (5) Trading Days after the tenth (10th) day following such Valuation Event by an independent, reputable appraiser jointly selected by the Company and the Holder.  The determination of such appraiser shall be final and
            binding upon all parties absent manifest error and the fees and expenses of such appraiser shall be borne by the Company. For purposes of hereof, “Adjustment Right” means
            any right granted with respect to any securities issued in connection with, or with respect to, any issuance or sale (or deemed issuance or sale in accordance with this Section 3(b)) of shares of Common Stock (other than rights of the type
            described in Section 3(c) and Section 3(d) hereof) that could result in a decrease in the net consideration received by the Company in connection with, or with respect to, such securities (including, without limitation, any cash settlement
            rights, cash adjustment or other similar rights).

      

    

    
      
         

          

        (v)       Record Date. If the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to receive a dividend or other distribution payable in shares of Common Stock, Options or in Common Stock Equivalents or (B)
            to subscribe for or purchase shares of Common Stock, Options or Common Stock Equivalents, then such record date will be deemed to be the date of the issuance or sale of the shares of Common Stock deemed to have been issued or sold upon the
            declaration of such dividend or the making of such other distribution or the date of the granting of such right of subscription or purchase (as the case may be).

      

    

    
      
         

          

        c)        Subsequent Rights Offerings.  In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to
              purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such
              Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
              hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
              the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder’s right to participate in any such Purchase Right would result in
              the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to
              such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

      

    

    
      
         

          

        d)        Pro Rata Distributions.  During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
            return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other
            similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such
            Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
            including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock
            are to be determined for the participation in such Distribution (provided, however, that, to the
            extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
            beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto
            would not result in the Holder exceeding the Beneficial Ownership Limitation).

      

    

    
      
        
          9

          
            

        

        e)        Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the
            Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct
            or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or
            property and has been accepted by the holders of 50.01% or more of the outstanding Common Stock or 50.01% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related
            transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or
            property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
            spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50.01% or more of the outstanding shares of Common Stock or 50.01% or more of the voting power of the common equity
            of the Company (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share
            that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of
            shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration in the form of cash, securities, property or otherwise (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such
            Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).  For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
            Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
            manner reflecting the relative value of any different components of the Alternate Consideration.  If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the
            Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.  Notwithstanding anything to the contrary, in the event of a Fundamental Transaction,
            the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public
            announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as
            defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company’s control, including not approved by
            the Company’s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of
            this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
            holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed
            to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.  “Black Scholes Value”
            means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined as of the day of
            consummation of the applicable contemplated Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public
            announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of
            the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the highest VWAP during the period beginning on the
            Trading Day immediately preceding the public announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder’s request
            pursuant to this Section 3(e), (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow.  The payment
            of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within five Business Days of the Holder’s election (or, if later, on the date of consummation of the Fundamental
            Transaction).  The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in
            writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
            (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
            similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon
            exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but
            taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
            protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental
            Transaction, the Successor Entity shall be added to the term “Company” under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant referring to the
            “Company” shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and
            power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor
            Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient
            authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.

      

    

    
      
        
          10

          
            

        

        f)         Calculations.
            All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a
            given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

      

    

    
      
         

          

        g)         Notice to Holder.

      

    

    
      
         

          

        i.         Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any
            resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

      

    

    
      
         

          

        ii.         Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
            (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
            be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory
            share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each
            case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least twenty (20) calendar days prior to the applicable record or effective date
            hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the
            Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to
            become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such
            reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be
            specified in such notice.  To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
            with the Commission pursuant to a Current Report on Form 8-K.  The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as
            may otherwise be expressly set forth herein.

      

    

    
      
        

        

         h)         Number of Warrant Shares. Simultaneous with any adjustment to the Exercise Price pursuant to Section 2(b) or Section 3(b)
            herein, the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the adjusted number of Warrant Shares
            shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment (without regard to any limitations on exercise contained herein).

          

         

          

        i)         Voluntary Adjustment By Company.  Subject to the rules and regulations of the Trading Market, the Company may, at any time while this Warrant is outstanding, reduce the then current Exercise Price to any amount and for any period of time deemed
            appropriate by the board of directors of the Company.

      

    

     

        

    Section 4.          Transfer of Warrant.

    
      
         

          

        a)        Transferability.  Subject to compliance with applicable securities laws, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
            together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.  Upon
            such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of
            assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.  Notwithstanding anything herein to the contrary, the Holder shall not be required
            to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder
            delivers an assignment form to the Company assigning this Warrant in full.  The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. 
            Notwithstanding anything herein to the contrary, the Company has no obligation to cause the Warrants to be listed on a national securities exchange or other trading market.

      

    

    
      
        
          11

          
            

        

        b)         New Warrants.  If this Warrant is not held in global form through DTC (or any successor depositary), this Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
            together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.  Subject to compliance with Section 4(a), as to any transfer which may be involved in
            such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall
            be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

      

    

    
      
         

          

        c)         Warrant Register. The Warrant Agent shall register this Warrant, upon records to be maintained by the Warrant Agent for that purpose (the “Warrant Register”), in
            the name of the record Holder hereof from time to time.  The Company and the Warrant Agent may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the
            Holder, and for all other purposes, absent actual notice to the contrary.

      

    

     

        

    Section 5.           Miscellaneous.

    
      
         

          

        a)          No Rights as Stockholder
              Until Exercise; No Settlement in Cash.  This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set
            forth in Section 2(d)(i), except as expressly set forth in Section 3.  Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i)
            and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.

      

    

    
      
         

          

        b)          Loss, Theft, Destruction
              or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock
            certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and
            cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

      

    

    
      
         

          

        c)         Saturdays, Sundays,
              Holidays, etc.  If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such
            right may be exercised on the next succeeding Business Day.

      

    

    
      
         

          

        d)         Authorized Shares.

      

    

     

    

    The Company covenants that, during the period the Warrant is exercisable, it will reserve from its authorized and unissued Common Stock
      a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its
      officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.  The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may
      be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.  The Company covenants that all Warrant Shares which may be issued upon the
      exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and
      nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

    
      12

      
        

    

    Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
      amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of
      the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against
      impairment.  Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all
      such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such
      authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

     

    

    Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in
      the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

    
      
         

          

        e)         Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in
              accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
              contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
              sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in
              connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
              any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
              or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall
              constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit
              or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the
              investigation, preparation and prosecution of such action or proceeding.

      

    

    
      
         

          

        f)         Restrictions.  The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state
            and federal securities laws.

      

    

    
      
         

          

        g)         Nonwaiver and Expenses.  No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies.  Without
            limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as
            shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise
            enforcing any of its rights, powers or remedies hereunder.

      

    

    
      
        
          13

          
            

        

        h)         Notices.  Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or
            sent by a nationally recognized overnight courier service, addressed to the Company, at 555 Wireless Blvd., Hauppauge, New York 11788, Attention: Larry
            Steenvoorden, Chief Financial Officer, email address: lsteenvoorden@chembio.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or
            deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder
            appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the
            e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in
            this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or
            (iv) upon actual receipt by the party to whom such notice is required to be given.  To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the
            Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.

      

    

    
      
         

          

        i)         Limitation of Liability.  No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to
            any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

      

    

    
      
         

          

        j)         Remedies.  The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant.  The Company agrees that
            monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a
            remedy at law would be adequate.

      

    

    
      
         

          

        k)         Successors and Assigns.  Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the
            successors and permitted assigns of Holder.  The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

      

    

    
      
         

          

        l)          Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and Holders or the beneficial owners of Warrants representing more than 50% of the Warrant
            Shares issuable under the Warrants then outstanding as of the date such consent is sought.  Notwithstanding the foregoing, only if this Warrant is issued in certificated form pursuant to a Warrant Exchange (as defined in the Warrant Agency
            Agreement), this Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.

      

    

    
      
         

          

        m)        Severability.  Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under
            applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

      

    

    
      
         

          

        n)         Headings.  The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

      

    

    
      
         

          

        o)        Warrant Agency Agreement.  If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued subject to the Warrant Agency Agreement.  To the extent any provision of this Warrant conflicts with the express
            provisions of the Warrant Agency Agreement, the provisions of this Warrant shall govern and be controlling.

            

          

      

    

    ********************

    

    

    (Signature Page Follows)

    
      14

      
        

    

    IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

    

    

    	 	
            CHEMBIO DIAGNOSTICS, INC.

          
	 	 
	 	
            By:

          	

          
	 	 	Name:
	 	 	Title:

    
      15

      
        

    

    NOTICE OF EXERCISE

    

    

    TO:          CHEMBIO DIAGNOSTICS, INC.

    

    

    (1)          The undersigned hereby elects to purchase ________ Warrant Shares of the Company
        pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

     

      

    (2)          Payment shall take the form of (check applicable box):

     

    

    [  ] in lawful money of the United States; or

     

    

    [ ] if permitted, the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to
      exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

     

      

    (3)          Please issue said Warrant Shares in the name of the undersigned or in such other
        name as is specified below:

     

    

    _______________________________

    

    

    The Warrant Shares shall be delivered to the following DWAC Account Number:

    

    

    _______________________________

    

    

    _______________________________

    

    

    _______________________________

    

    

    [SIGNATURE OF HOLDER]

    

    

    	
            Name of Investing Entity:

          	 

    	
            Signature of Authorized Signatory of Investing
                Entity:

          	 

    	
            Name of Authorized Signatory:

          	 

    	
            Title of Authorized Signatory:

          	 

    	
            Date:

          	 

    
      
        

    

    ASSIGNMENT FORM

    

    

    (To assign the foregoing Warrant, execute this form and supply required information.  Do not use this form to purchase shares.)

     

    

    FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

     

    

    	
            Name:

          	 	 	 	 
	 	 	 	
            (Please Print)

          	 
	 	 	 	 	 
	
            Address:

          	 	 	 	 
	 	 	 	(Please Print) 

          	 
	 	 	 	 	 
	
            Phone Number:

          	 	 	
            

            

          	 
	 	 	 	 	 
	Email Address:	 	 	 	 
	 	 	 	 	 
	
            Dated: _______________ __, ______

          	 	 	 
	 	 	 	 
	
            Holder’s Signature:          

          	 	 	 	 
	 	 	 	 	 
	
            Holder’s Address:Exhibit 10.5

 

CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY
HARMFUL IF PUBLICLY DISCLOSED.

 

 

 

June 24, 2022

 

VIA E-MAIL

 

Steve R. Carchedi

[***]

 

Dear Steve:

 

The purpose of this letter agreement
(“Agreement”) is to confirm the terms of your separation from Allarity Therapeutics, Inc. (the “Company”).1
Unless you rescind your assent as set forth in Section 6 below, this Agreement shall be effective on the eighth (8th)
day following your signing of this Agreement (the “Effective Date”), at which time it shall become final and binding
on all parties. The Consideration described below is contingent on your agreement to and compliance with the provisions of this Agreement.

 

1.   Separation
Date. Your employment with the Company will terminate effective June 29, 2022 (the “Separation Date”). On the Separation
Date, you will resign from the Company and all of its subsidiaries in all capacities (including as a director of the Company) and the
Company will exercise its right to accelerate the effective date of your resignation to June 29, 2022. On or about the Separation Date,
the Company will pay you your final pay for wages earned through the Separation Date and all of your accrued but unused vacation time
in accordance with the law.

 

2.   Consideration.
If you sign and do not rescind this Agreement as set forth in Section 6 below, then the Company will provide you with the following payments
and benefits (collectively, the Consideration”):

 

		(i)	[***];

 

 

	1	Except for the obligations set forth in Section 2 of this Agreement,
which shall be the sole obligation of Allarity Therapeutics, Inc., whenever the terms “Allarity” or the “Company”
are used in this Agreement (including, without limitation, Section 6), they shall be deemed to include Allarity Therapeutics, Inc., Oncology
Venture NS, and any related companies (including, without limitation, any divisions, franchisees, licensees, affiliates, parents
and subsidiaries), and its and their respective officers, directors, trustees, employees, agents, successors, predecessors and assigns.

 

    

     

    

 

		(ii)	Salary continuation at your current base salary for a period of [***] months ($[***] per month), subject
to all ordinary payroll taxes, which will be provided as salary continuation in accordance with the Company’s regular payroll processing
schedule, with the first payment commencing on the first regular pay date following the Effective Date of this Agreement and the first
such payment shall be retroactive to the day immediately following the Separation Date; and

 

		(iii)	Regardless of whether you execute this Agreement, and provided you timely
complete the required election forms, you are eligible to continue receiving group medical, dental and/or vision insurance pursuant to
the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”). If you sign
and do not rescind this Agreement, and provided you timely complete the COBRA election forms, then the Company will pay the full cost
of the group insurance premiums for said coverage for [***] months (through [***]). After [***], you are responsible for paying the full
cost of the group medical, dental and/or vision insurance premiums, if you elect to continue your participation under COBRA, for the balance
of time provided by the statute (provided, however, the “qualifying event” under COBRA shall be deemed to have occurred on the
Separation Date).

 

		(iv)	With respect to all or your vested stock options (including warrants of Allarity Therapeutics A/S converted
into stock options of the Company), vesting will cease upon the Separation Date and you will be permitted to exercise your vested options
for a period of ninety (90) days from the Separation Date. Thereafter, all vested options will expire.

 

 3. Acknowledgments. You acknowledge and agree that:

 

		(i)	this Agreement and the Consideration are neither intended to nor shall constitute
a severance plan and shall confer no benefit on anyone other than the Company and you;

 

		(ii)	based on your resignation effective immediately, the Consideration provided for
herein is not otherwise due or owing to you under any Company policy or any employment agreement (oral or written);

 

		(iii)	except for (a) any unpaid wages and/or vacation time accrued through the Separation Date, which are to
be paid by the Company on or about the Separation Date, and (b) any vested monies due to you pursuant to the Company’s 401(k) savings
plan, you have been paid and provided all wages, vacation pay, earned sick leave, family and medical leave, holiday pay, commissions,
bonuses and any other form of compensation or benefit that may be due to you now or which would have become due in the future in connection
with your employment with or separation of employment from the Company; and

 

    2

     

    

 

		(iv)	in order to be reimbursed for outstanding business expenses that you may have incurred on behalf of
the Company, all expense reports and supporting documentation must be submitted to the Company on or before August 31, 2022.

 

4.   Unemployment
Insurance. You may seek unemployment benefits as a result of your separation from the Company. Decisions regarding eligibility for
and amounts of unemployment benefits are made by the applicable state agency, not by the Company. A completed Employer Information
Form (Form UC-1609 REV 04-20) required by the Pennsylvania Department of Labor & Industry Office of Unemployment Compensation
Benefits Policy is included with this letter.

 

5.   Return
of Company Property; Confidentiality; Non-Disparagement. You hereby covenant and agree to:

 

		(i)	promptly return to the Company, all property and documents (whether in hard copy or electronic form)
of the Company in your custody and possession, including (without limitation) any Company-issued laptop computer, Company issued cellphone,
any and all Company-issued electronic equipment and devices, files, documents, records, tools, access badges and cards, and keys;

 

		(ii)	abide by the terms of the Service Agreement between you and the Company, (the “Employment Agreement”);

 

		(iii)	abide by any and all common law and/or statutory obligations relating to the protection and non-disclosure
of the Company’s trade secrets and/or confidential and proprietary documents and information, and you specifically agree that you will
not disclose any confidential or proprietary information that you acquired as an employee of the Company to any other person or entity,
or use such information in any manner that is detrimental to the interests of the Company. Further, notwithstanding your confidentiality
and nondisclosure obligations, you are hereby advised as follows pursuant to the Defend Trade Secrets Act: “An individual shall not
be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made
(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely
for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a
lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit for retaliation by an employer for reporting
a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the
court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade
secret, except pursuant to court order”;

 

		(iv)	keep confidential and not publicize or disclose the existence and terms
of this Agreement, other than to (a) an immediate family member, legal counsel, accountant or financial advisor, provided that any such
individual to whom disclosure is made shall be bound by these confidentiality obligations; or (b) a
state or federal tax authority or government agency to which disclosure is mandated by applicable state or federal law; and

 

    3

     

    

 

		(v)	not make any statements that are disparaging about or adverse to the business interests of the Company
or which are intended to harm the reputation of the Company, including, but not limited to, any statements that disparage any product,
service, finances, employees, officers, directors, capability or any other aspect of the business of Company; provided, however, the foregoing
will not be violated by truthful statements made by you about the Company’s products, services, finances, employees, officers, directors,
capability or any other aspect of the business of the Company in response to a lawfully issued subpoena. The Company agrees that the executive
officers of the Company and members of the Board of Directors as of the Separation Date will not make negative comments about you or otherwise
disparage you in any manner that is likely to be harmful to your business reputation, provided, however, the foregoing will not be violated
by truthful statements made by executive officers of the Company and members of the Board of Directors, in response to a lawfully issued
subpoena.

 

A breach of this Section 5
will constitute a material breach of this Agreement and, in addition to any other legal or equitable remedy available, will entitle the
Company to stop providing and/or recover any Consideration.

 

 6. Release of Claims.

 

		(i)	You hereby acknowledge and agree that by signing this Agreement and accepting
the Consideration, you are waiving your right (for yourself, your spouse, your heirs, executors, administrators and assigns) to assert
any form of legal claim against Company (as defined in footnote number 1) of any kind whatsoever from the beginning of time through and
including the date of your execution of this Agreement, except for claims related to the Company’s failure to perform its obligations
under this Agreement. Your waiver and release is intended to bar any form of legal claim, charge, complaint or any other form of action
(jointly referred to as “Claims”) against Company seeking any form ofrelief including,
without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages or any other form of
monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional distress damages, punitive
damages, attorneys’ fees and any other costs) against Company up through and including the date of your execution of this Agreement. You
understand that there could be unknown or unanticipated Claims resulting from your employment with Company and the termination thereof
and agree that such Claims are intended to be, and are, included in this waiver and release.

 

		(ii)	Without limiting the foregoing general waiver and release in the previous paragraph, you specifically
waive and release the Company from any Claims arising from or related to your employment relationship with the Company or the termination
thereof, including without limitation:

 

		(a)	Claims under any local, state or federal discrimination, harassment, fair employment practices or other
employment related statute, regulation or executive order, including, without limitation, the Pennsylvania Human Relations Act,

 

    4

     

    

 

Massachusetts Fair Employment Practices Act
(also known as Chapter 151B), the Age Discrimination in Employment Act, the Older Workers Benefits Protection Act (“OWBPA”),
the Americans with Disabilities Act, the Genetic Information Nondiscrimination Act, the Pregnancy Discrimination Act, the Worker

 

Adjustment
and Retraining Notification Act, the National Labor Relations Act, the Civil Rights Act of 1991, and Title VII of the Civil Rights Act
of 1964, each as they may have been amended through the Effective Date;

 

		(b)	Claims under any local, state or federal employment related statute, regulation or executive order relating
to wages, hours, whistleblowing, leaves of absence or any other terms and conditions of employment, including, without limitation, the
Fair Labor Standards Act, the Equal Pay Act of 1963, the Family and Medical Leave Act, the Pennsylvania Wage Payment and Collection Law,
the Massachusetts Paid Family and Medical Leave Act, the Massachusetts Earned Sick Time Law, the Massachusetts Payment of Wages Law (Massachusetts
General Laws Chapter 149, §§ 148, 150), Massachusetts General Laws Chapter 149 in its entirety and Massachusetts General Laws
Chapter 151 in its entirety (including, without limitation, the sections concerning payment of wages, minimum wage and overtime), each
as they may have been amended through the Effective Date. You specifically acknowledge that you are waiving any Claims for unpaid wages
under these and other statutes, regulations and executive orders;

 

		(c)	Claims under any local, state or federal common law theory; and

 

		(d)	any other Claim arising under other local, state or federal law.

 

		(iii)	The general release in this Section 6 is not affected or limited by the recitation of the specific
releases in this Section 6.

 

		(iv)	Because you are over 40 years of age, you are granted specific rights under the Older Workers Benefit
Protection Act (“OWBPA”) and the Age Discrimination in Employment Act (“ADEA”), which prohibits discrimination
on the basis of age. The release set forth in this Section 6 is intended to release any rights you may have against the Company alleging
discrimination on the basis of age. Consistent with the OWBPA and your Employment Agreement, you have sixty (60) days to consider and
accept the provisions of this Agreement, and you agree that any changes to this Agreement, whether material or immaterial, will not restart
the running of this 60-day period. In addition, you may rescind your assent to this Agreement if, within seven (7) days after the date
you sign this Agreement, you deliver a written notice of rescission. To be effective, such notice of rescission must be hand-delivered
to or postmarked and sent by certified mail, return receipt requested, within the seven-day period to Duncan Moore, Chairman of the Board,
Allarity Therapeutics, Inc. c/o Scott E. Bartel, Esq. 633 West 5th Street, Suite 4000, Los Angeles, CA 90071, with copies by
email to Duncan Moore at dmoore@allarity.com, Thomas Lent, Esq. at tlent@marbarlaw.com and Scott E. Bartel, Esq. at scott.bartel@lewisbrisbois.com.

 

		(v)	Consistent with federal and state discrimination laws, nothing in this release shall be deemed to prohibit
you from challenging the validity of this release under federal or state discrimination laws or from filing a charge or complaint of age
or other employment related discrimination with the Equal Employment Opportunity Commission (“EEOC’) or similar state agency,
or from participating in any investigation or proceeding conducted by the EEOC or similar state agency.

 

    5

     

    

 

Further, nothing in this release
or Agreement shall be deemed to limit Company’s right to seek immediate dismissal of such charge or complaint on the basis that your signing
of this Agreement constitutes a full release of any individual rights under federal or state discrimination laws, or Company’s right to
seek restitution or other legal remedies to the extent permitted by law of the economic benefits provided to you under this Agreement
in the event that you successfully challenge the validity of this release and prevail in any claim under federal or state discrimination
laws.

 

		(vi)	The general release in this Section 6 shall not limit any right you may have to receive a whistleblower
award or bounty for information provided to the Securities and Exchange Commission.

 

7.   No
Prior Actions. You represent that you have not filed or asserted any cause of action, claim, charge or other action or proceeding
against the Company, and to the best of your knowledge, no other person, organization or entity has done so on your behalf.

 

8.   Cooperation.
You agree to reasonably cooperate with the Company in any internal investigation or administrative, regulatory, or judicial proceeding.
You understand and agree that your cooperation may include, but is not limited to, making yourself available to the Company upon reasonable
notice for interviews and factual investigations, appearing at the Company’s request to give testimony without requiring service of a
subpoena or other legal process, volunteering to the Company pertinent information, and turning over to the Company all relevant documents
which are or may come into your possession all at times and on schedules that are reasonably consistent with your other permitted activities
and commitments. In addition, you agree to reasonably cooperate with Company management in the transfer
of information that you may have relating to the Company that is not included in the files and other information that was returned to
the Company pursuant to Section 5(i) above. In the event that the Company asks for your cooperation, the Company will reimburse you for
all reasonable expenses related to such cooperation provided, however, that the Company shall not be required to reimburse you for any
attorneys’ fees otherwise reimbursable to you pursuant to any right of indemnification you may have in accordance with the provisions
of the Employment Agreement.

 

 9. Miscellaneous.

 

		(i)	This Agreement supersedes any and all prior oral and/or written agreements and sets forth the entire agreement
between the Company and you with respect to your separation from the Company except for the post-termination restrictive covenants contained
in the agreement referenced in Section 5(ii), which shall remain in full force and effect.

 

		(ii)	No variations or modifications hereof shall be deemed valid unless reduced to writing and signed by
the Company and you.

 

		(iii)	The provisions of this Agreement are severable, and if for any reason any part hereof shall be found
to be unenforceable, the remaining provisions shall be enforced in full.

 

    6

     

    

 

		(iv)	The validity, interpretation and performance of this Agreement, and any
and all other matters relating to your employment and separation of employment from the Company, shall be governed by and construed in
accordance with the internal laws of the Commonwealth of Pennsylvania, without giving effect to conflict of law principles. Both parties
agree that any action, demand, claim or counterclaim relating to (a) your employment and separation of your employment, and/or (b)
the terms and provisions of this Agreement or to its breach, shall be commenced only and exclusively in
the Commonwealth of Pennsylvania in a court of competent jurisdiction, and both parties hereby consent to said jurisdiction.

 

		(v)	Both parties further agree that any such dispute shall be tried by a judge alone,
and both parties hereby waive and forever renounce the right to a trial before a civil jury in any such dispute.

 

It is the Company’s desire and
intent to make certain that you fully understand the provisions and effects of this Agreement. To that end, you have been encouraged and
given an opportunity to consult with legal counsel, and you acknowledge having done so. By executing this Agreement, you are acknowledging
that (a) you have been afforded sufficient time to understand the provisions and effects of this Agreement and to consult with legal counsel;
(b) your agreements and obligations under this Agreement are made voluntarily, knowingly and without duress; and (c) neither the Company
nor its agents or representatives have made any representations inconsistent with the provisions of this Agreement.

 

If the foregoing correctly sets
forth our arrangement, please sign under seal, date and return the enclosed copy of this Agreement to Duncan Moore, Chairman, Allarity
Therapeutics, Inc., via email at dmoore@allarity.com, with copies to Thomas Lent, Esq., tlent@marbarlaw.com and scott.bartel@lewisbrisbois.com
within the time frame set forth above but not on or before the Separation Date.

 

Sincerely,

 

		 	 	 
	Duncan Moore	 	 	 
	Chairman	 	 	 
	 	 	 	 
	Accepted and Agreed To under Seal:	 	 	 
	 	 	 	 
		 	 	
	Steve R. Carchedi	 	 	Date

 

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]